24 results
The objectives of the study are as follows:*1. To assess the effectiveness of inhaled PA101 delivered via eFlow high efficiency nebulizer for treating chronic cough. Improvements in chronic cough will be assessed by measuring the change from…
Primary: To demonstrate that the efficacy of secukinumab 150 mg s.c. or 300 mg s.c., at Week 24 is superior to placebobased on proportion of subjects achieving ACR20 response in subjects with active PsA.Secondary:- mTTS structural damage week 24-…
To study whether rivastigmine added to treatment with haloperidol shortens the duration of delirium in ICU patients and reduces costs.
To evaluate whether preventive treament with haloperidol lowers the risk for delirium in stroke patients with an increased risk for delirium.
The current study is designed as a first exploration of this model. The hypothesis is that haloperidol will lead to an amelioration of the *psychotomimetic* effects of the THC-challenge.
Primary: To demonstrate the efficacy of each secukinumab regimen at Week 16 is superior to placebo in patients with active AS based on the proportion of patients achieving an ASAS 20 response in the subgroup of patients who are TNFα inhibitor naïve.…
The role of dopamine in bias and disengagement, two mechanisms implicated in visuospatial attention.
To gain insight in the role of the dopaminergic system in two components of visuospatial attention, bias and disengagement.
The purpose of this study is to investigate the role of dopamine in learning about sexual reward in healthy females. We suppose that repeated associations between a neutral stimulus and sexual stimulation results, through classical conditioning, in…
Primary: To demonstrate the efficacy of one or both secukinumab regimens at Week 16 is superior to placebo in patients with active AS based on the proportion of patients achieving an ASAS 20 response.Secondary (key only): ASAS40 week 16 response in…
Primary objective(s):To evaluate the effect of early haloperidol prophylaxis on the incidence, severity and duration of in-hospital delirium in at-risk patients aged 70 years and over who are acutely admitted to the hospital through the ED, for…
Main Objective:To demonstrate the efficacy of secukinumab compared to placebo withrespect to HiSCR after 16 weeks of treatment.Secondary objective:To demonstrate the efficacy of secukinumab compared to placebo after 16 weeks of treatment with…
The purpose of this clinical research extension study is to evaluate whether prolonged treatment with secukinumab for up to another 4 years (Week 52 to Week 260) will bring benefits and be safe to patients with moderate to severe HS. The main…
• To assess the effect of lorazepam compared to placebo on stability (Body Sway) in relation to stabilizing subsystems (BalRoom) in healthy elderly.• To assess the effect of haloperidol compared to placebo on stability (Body Sway) in relation to…
In this study we aim to examine the effects of a low dosage of prophylactic haloperidol in patients with an expected ICU length of stay of >1 day. We use two different dosages of haloperidol in this study to compare with placebo. A dosage of…
Primary: To demonstrate the efficacy of one or both secukinumab regimens at Week 16 is superior to placebo in patients with active AS based on the proportion of patients achieving an ASAS 40 response.Secondary (key only): ASAS responses in the…
This study is designed to leverage the sensitivity of ultrasonography available in clinical practice setting to better describe the time course of response to secukinumab (150 mg and 300 mg) on joint synovitis and enthesitis in PsA patients with an…
This study aims to clarify whether the brain dopamine and noradrenaline system underlie the electrocortical responses (event-related potentials) that are sensitive to cues signalling reward and probability, the P200 and P300.
The purpose of the study is to investigate the use of secukinumab (AIN457) treat ment in children from 2 to18 years of age with either active Enthesitis -Related Arthritis (ERA) or Juvenile Psoriatic Arthritis (JPsA) subtypes of Juvenile Idiopathic…
Primary: To demonstrate that the efficacy of secukinumab 150 mg s.c. or 300 mg s.c., at Week 24 is superior to placebo based on proportion of subjects achieving ACR20 response in subjects with active PsA.Secondary:- PASI75 week 24- PASI90 week 24-…
Primary: To demonstrate the efficacy of one or both secukinumab regimens at Week 16 is superior to placebo in patients with active AS based on the proportion of patients achieving an ASAS 20 response in the subgroup of patients who are TNF*…